High azithromycin loading powders for inhalation and their in vivo evaluation in rats

International Journal of Pharmaceutics

Volumn 395, Issue 1-2, 2010, Pages 205-214

  Zhang, Yu ^a   Wang, Xiaoli ^a   Lin, Xia ^a   Liu, Xiaoliang ^b   Tian, Bin ^a   Tang, Xing ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Liaoning Pharmaceutical Industry Co Ltd   (China)

Author keywords

Azithromycin; Central composite rotatable design; Dry powder inhalation; Lung epithelial lining fluid; Microdialysis; Pulmonary delivery

Indexed keywords

AZITHROMYCIN; AEROSOL; ANTIINFECTIVE AGENT; POWDER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRY POWDER; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; POWDER INHALER; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPE; SPRAY DRYING; AEROSOL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; DRUG FORMULATION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MALE; MEDICINAL CHEMISTRY; METABOLISM; NEBULIZER; PARTICLE SIZE; POWDER; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; INJECTIONS, INTRAVENOUS; LUNG; MALE; MICRODIALYSIS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 77954309361     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.05.043     Document Type: Article

References (58)

1. Ahsan F., Rivas I.P., Khan M.A., Torres Suarez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers - liposomes and microspheres - on the phagocytosis by macrophages. J. Control Release 2002, 79:29-40.
2. Arnold M.M., Gorman E.M., Schieber L.J., Munson E.J., Berkland C. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release 2007, 121:100-109.
3. Atkins P.J. Dry powder inhalers: an overview. Respir. Care 2005, 50:1304-1312. (discussion 1312).
4. Blumer J.L. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int. J. Antimicrob. Agents 2005, 26:143-147.
5. Bosquillon C., Preat V., Vanbever R. Pulmonary delivery of growth hormone using dry powders and visualization of its local fate in rats. J. Control. Release 2004, 96:233-244.
6. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Preat V., Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 2004, 99:357-367.
7. Brunner M., Pernerstorfer T., Mayer B.X., Eichler H.G., Muller M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit. Care Med. 2000, 28:1754-1759.
8. Chan H.K., Clark A., Gonda I., Mumenthaler M., Hsu C. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 1997, 14:431-437.
9. Chen L., Qin F., Ma Y., Li F. Quantitative determination of azithromycin in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study. J. Chromatogr. B 2007, 855:255-261.
10. Chopra S., Motwani S.K., Iqbal Z., Talegaonkar S., Ahmad F.J., Khar R.K. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design. Eur. J. Pharm. Biopharm. 2007, 67:120-131.
11. Chougule M.B., Padhi B.K., Jinturkar K.A., Misra A. Development of dry powder inhalers. Recent Pat. Drug Deliv. Formul. 2007, 1:11-21.
12. Corrigan D.O., Corrigan O.I., Healy A.M. Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems. Int. J. Pharm. 2004, 273:171-182.
13. Corrigan D.O., Corrigan O.I., Healy A.M. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers. Int. J. Pharm. 2006, 322:22-30.
14. Costantino H.R., Andya J.D., Nguyen P.A., Dasovich N., Sweeney T.D., Shire S.J., Hsu C.C., Maa Y.F. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 1998, 87:1406-1411.
15. de Lange E.C., de Boer A.G., Breimer D.D. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv. Drug Deliv. Rev. 2000, 45:125-148.
16. Eisenberg E.J., Conzentino P., Eickhoff W.M., Cundy K.C. Pharmacokinetic measurement of drugs in lung epithelial lining fluid by microdialysis: aminoglycoside antibiotics in rat bronchi. J. Pharmacol. Toxicol. Methods 1993, 29:93-98.
17. El-Gendy N., Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res. 2009, 26:1752-1763.
18. Giovagnoli S., Blasi P., Schoubben A., Rossi C., Ricci M. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int. J. Pharm. 2007, 333:103-111.
19. Gliniski J., Chavepeyer G., Platten J.K. Surface properties of aqueous solutions of l-leucine. Biophys. Chem. 2000, 84:99-103.
20. Goldman J.M., Bayston S.M., O'Connor S., Meigh R.E. Inhaled micronised gentamicin powder: a new delivery system. Thorax 1990, 45:939-940.
21. Hagerman J.K., Hancock K.E., Klepser M.E. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin. Drug Deliv. 2006, 3:71-86.
22. Hall I.H., Schwab U.E., Ward E.S., Butts J.D., Wolford E.T., Ives T.J. Disposition and intracellular activity of azithromycin in human THP-1 acute monocytes. Int. J. Antimicrob. Agents 2002, 20:348-360.
23. Hand W.L., Hand D.L. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents 2001, 18:419-425.
24. Herkner H., Muller M.R., Kreischitz N., Mayer B.X., Frossard M., Joukhadar C., Klein N., Lackner E., Muller M. Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am. J. Respir. Crit. Care Med. 2002, 165:273-276.
25. Hoepelman I.M., Schneider M.M. Azithromycin: the first of the tissue-selective azalides. Int. J. Antimicrob. Agents 1995, 5:145-167.
26. Islam N., Gladki E. Dry powder inhalers (DPIs) - a review of device reliability and innovation. Int. J. Pharm. 2008, 360:1-11.
27. Joukhadar C., Derendorf H., Muller M. Microdialysis. A novel tool for clinical studies of anti-infective agents. Eur. J. Clin. Pharmacol. 2001, 57:211-219.
28. Joukhadar C., Frossard M., Mayer B.X., Brunner M., Klein N., Siostrzonek P., Eichler H.G., Muller M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med. 2001, 29:385-391.
29. Kasahara K., Maeda K., Mikasa K., Uno K., Takahashi K., Konishi M., Yoshimoto E., Murakawa K., Kita E., Kimura H. Longterm azithromycin therapy for three patients with chronic lower respiratory tract infections. J. Infect. Chemother. 2004, 10:42-45.
30. Kohlhammer Y., Raspe H., Marre R., Suttorp N., Welte T., Schafer T. Antibiotic treatment of community acquired pneumonia varies widely across Germany. J. Infect. 2007, 54:446-453.
31. Kollef M.H. The importance of antimicrobial resistance in hospital-acquired and ventilator-associated pneumonia. Curr. Anaesth. Crit. Care 2005, 16:209-219.
32. Learoyd T.P., Burrows J.L., French E., Seville P.C. Chitosan-based spray-dried respirable powders for sustained delivery of terbutaline sulfate. Eur. J. Pharm. Biopharm. 2008, 68:224-234.
33. Li F.Q., Hu J.H., Lu B., Yao H., Zhang W.G. Ciprofloxacin-loaded bovine serum albumin microspheres: preparation and drug-release in vitro. J. Microencapsul. 2001, 18:825-829.
34. Li H.Y., Neill H., Innocent R., Seville P., Williamson I., Birchall J.C. Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. J. Drug Target. 2003, 11:425-432.
35. Li H.Y., Seville P.C., Williamson I.J., Birchall J.C. The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J. Gene Med. 2005, 7:343-353.
36. Li J., Nie S., Yang X., Wang C., Cui S., Pan W. Optimization of tocol emulsions for the intravenous delivery of clarithromycin. Int. J. Pharm. 2008, 356:282-290.
37. Mitchell M.A. Azithromycin. Seminars in Avian and Exotic Pet Medicine, 14 2005, 212-214.
38. Mosen K., Backstrom K., Thalberg K., Schaefer T., Kristensen H.G., Axelsson A. Particle formation and capture during spray drying of inhalable particles. Pharm. Dev. Technol. 2004, 9:409-417.
39. Nicasio A.M., Eagye K.J., Nicolau D.P., Shore E., Palter M., Pepe J., Kuti J.L. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J. Crit. Care 2009.
40. O'Doherty B., Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur. J. Clin. Microbiol. Infect. Dis. 1998, 17:828-833.
41. Ohashi K., Kabasawa T., Ozeki T., Okada H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release 2009, 135:19-24.
42. Pai V.B., Nahata M.C. Efficacy and safety of aerosolized tobramycin in cystic fibrosis. Pediatr. Pulmonol. 2001, 32:314-327.
43. Pilcer G., Sebti T., Amighi K. Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation. Pharm. Res. 2006, 23:931-940.
44. Rabbani N.R., Seville P.C. The influence of formulation components on the aerosolisation properties of spray-dried powders. J. Control. Release 2005, 110:130-140.
45. Rennard S.I., Basset G., Lecossier D., O'Donnell K.M., Pinkston P., Martin P.G., Crystal R.G. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. 1986, 60:532.
46. Schanker L.S., Less M.J. Lung pH and pulmonary absorption of nonvolatile drugs in the rat. Drug Metab. Dispos. 1977, 5:174-178.
47. Seville P.C., Learoyd T.P., Li H.Y., Williamson I.J., Birchall J.C. Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery. Powder Technol. 2007, 178:40-50.
48. Son Y.J., McConville J.T. Advancements in dry powder delivery to the lung. Drug Dev. Ind. Pharm. 2008, 34:948-959.
49. Steckel H., Brandes H.G. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 2004, 278:187-195.
50. Todo H., Iida K., Okamoto H., Danjo K. Improvement of insulin absorption from intratracheally administrated dry powder prepared by supercritical carbon dioxide process. J. Pharm. Sci. 2003, 92:2475-2486.
51. Twiss J., Byrnes C., Johnson R., Holland D. Nebulised gentamicin-suitable for childhood bronchiectasis. Int. J. Pharm. 2005, 295:113-119.
52. Ventura C.A., Tommasini S., Crupi E., Giannone I., Cardile V., Musumeci T., Puglisi G. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. Eur. J. Pharm. Biopharm. 2008, 68:235-244.
53. Wu J.W., Shih H.H., Wang S.C., Tsai T.H. Determination and pharmacokinetic profile of pyrazinamide in rat blood, brain and bile using microdialysis coupled with. Anal. Chim. Acta 2004, 522:231-239.
54. Young P.M., Cocconi D., Colombo P., Bettini R., Price R., Steele D.F., Tobyn M.J. Characterization of a surface modified dry powder inhalation carrier prepared by " particle smoothing" J. Pharm. Pharmacol. 2002, 54:1339-1344.
55. Zeitlinger M., Müller M., Joukhadar C. Lung microdialysis-a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J. 2005, 7:600-608.
56. Zeng X.M., Martin G.P., Tee S.K., Marriott C. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int. J. Pharm. 1998, 176:99-110.
57. Zhang Y., Liu X., Cui Y., Huang H., Chi N., Tang X. Aspects of degradation kinetics of azithromycin in aqueous solution. Chromatographia 2009, 70:67-73.
58. Zhao M., You Y., Ren Y., Zhang Y., Tang X. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying. Powder Technol. 2008, 187:214-221.